Humacyte KOL Event on Vascular Trauma: Ukrainian Surgeons on the Use of Human Acellular Vessels™ in Wartime
|DATE:||December 15, 2022|
|TIME:||8:00 AM EST|
About The Event
Join us for a KOL Event with Humacyte to discuss its Human Acellular Vessels™ (HAV), a tissue-engineered blood vessel, as a potential treatment option for vascular trauma in a wartime setting. The event will feature presentations from Ukrainian surgeons discussing multiple cases of HAV use to treat war zone induced vascular trauma.
The HAV has received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense, it is highly resistant to infection and is designed to offer off-the-shelf availability for the repair of injured blood vessels. The HAV is made in a bioreactor bag that can be shipped, stored, and be immediately available when needed. The HAV is designed to address long-standing limitations of vascular tissue repair and replacement in acute injuries, both in civilian and combat settings.
A live Q&A session will follow the formal presentations.